Healthcare Industry News: multiple myeloma
News Release - September 12, 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical DevelopmentNEWTON, Mass., Sept. 12, 2016 -- (Healthcare Sales & Marketing Network) -- Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD, FCAP, as Senior Vice President, Clinical Development. Dr. Gardner will be responsible for clinical development planning and strategy, including building and leading clinical teams to achieve the Company’s long-term strategic objectives, and will report to Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm.
“Dr. Gardner’s extensive clinical and industry experience will be invaluable to Karyopharm as we continue forward with advancing our lead, novel, oral Selective Inhibitor of Nuclear Export (SINE™) compound, selinexor, as well as our other wholly-owned pipeline programs,” said Dr. Shacham. “I am pleased to welcome Dr. Gardner to the Karyopharm team, and look forward to leveraging his expertise as we strive towards our ultimate goal of providing novel, effective new therapeutic options to patients with inadequately treated cancers.”
“It is an honor to join Karyopharm at such a pivotal point in the Company’s history, and I look forward to working with Drs. Kauffman and Shacham and the rest of the leadership team to advance and expand selinexor clinical development activities,” said Dr. Gardner. “We believe this promising therapy holds great potential as a much needed treatment option for patients suffering from diseases with high unmet needs, including those with both heavily pretreated and earlier relapsed multiple myeloma.”
Dr. Gardner brings more than 25 years of experience in industry and academic clinical research to Karyopharm, with a strong track record in oncology drug development. He most recently served as Clinical Vice President of Translational Medicine at AstraZeneca, where he oversaw Oncology Translational Medicine at AstraZeneca’s Boston site and served as Medical Science Director for multiple clinical-stage oncology programs, including multiple programs incorporating small molecule and immuno-oncology compounds. Before joining AstraZeneca in 2011, he served as Senior Director and Global Head of Oncology Translational Laboratories at Novartis, and as Associate Director and Head of Research Pathology at Biogen Idec. Prior to his extensive industry experience, Dr. Gardner was an Assistant Professor at the Scripps Research Institute, and held clinical posts including Associate Pathologist at the Veterans Association and Resident in Anatomical Pathology at Beth Israel Hospital, Harvard Medical School. He received postdoctoral training at the Whitehead Institute of MIT, and his Medical Degree and Bachelor’s Degree in Biochemistry at the University of Cambridge in the United Kingdom.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,600 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in acute myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others. Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.
Source: Karyopharm Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.